Stewart Fisher - Dec 8, 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Scientific Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Dec 8, 2021
Transactions value $
$73,000
Form type
4
Date filed
12/10/2021, 03:30 PM
Previous filing
Aug 5, 2021
Next filing
Feb 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise $5.01K +2.37K +10.43% $2.11 25.1K Dec 8, 2021 Direct
transaction CCCC Common Stock Options Exercise $66K +17.8K +70.81% $3.71 42.9K Dec 8, 2021 Direct
transaction CCCC Common Stock Options Exercise $2.01K +403 +0.94% $4.98 43.3K Dec 8, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -2.37K -100% $0.00* 0 Dec 8, 2021 Common Stock 2.37K $2.11 Direct F1
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -17.8K -32.04% $0.00 37.7K Dec 8, 2021 Common Stock 17.8K $3.71 Direct F2
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -403 -0.2% $0.00 204K Dec 8, 2021 Common Stock 403 $4.98 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested and exercisable as of the date hereof.
F2 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter.
F3 This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020.